HemostOD is a seed financed start-up developing in-vitro human platelets. It has 10 staff, 8 of which are based at laboratories on the EPFL Innovation park in Lausanne. With operations commencing in 2021, HemostOD's next milestone is a pre-IND meeting in 2026 and commencement of IND studies.
Some insights
The co-founders are experienced entrepreneurs with track records in M&A and pharma who in-licensed the basic technology on human platelet manufacture.The current R&D team with skills in advanced biology and engineering has translated this into a viable process and has built a secure IP portfolio.